From the paper:
Study staff verified eligibility criteria including ... SARS-CoV-2 infection within 10 days (positive polymerase chain reaction or antigen test result, including home-based tests)
Infection is when symptoms start, not the time of exposure.
Within 10 days of symptoms/infection is way too long of a window. It needs to be 4 days to be a proper antiviral study. Again, the people who studied Paxlovid understood this. If they can, so should these authors. If they are waiting on a PCR test result, I imagine that moves the fastest time to treat in the wrong direction.
In my opinion, if you get so much as a slight headache, start taking IVM right away, and take a test and add fluvoxamine and/or nitazoxanide (per FLCCC protocols) if the test comes back positive. Personally, I skip the tests because I only get headaches when sick and little else was floating around in 2020-2022. In 2023, I would still skip the test and assume covid if someone else tested positive that I might have been exposed to, or were exposed at the same time as me.
It looks like they were A/B testing with fluvoxamine, with some "non active agent" as a placebo. Which, again, both of these drugs are useless as an antiviral unless they prove that these were taken within 4 days of infection.
From the paper:
Study staff verified eligibility criteria including ... SARS-CoV-2 infection within 10 days (positive polymerase chain reaction or antigen test result, including home-based tests)
Infection is when symptoms start, not the time of exposure.
Within 10 days of symptoms/infection is way too long of a window. If they are waiting on a PCR test result, I imagine that moves the fastest time to treat in the wrong direction.
In my opinion, if you get so much as a slight headache, start taking IVM right away, and take a test and add fluvoxamine and/or nitazoxanide (per FLCCC protocols) if the test comes back positive. Personally, I skip the tests because I only get headaches when sick and little else was floating around in 2020-2022. In 2023, I would still skip the test and assume covid if someone else tested positive that I might have been exposed to, or were exposed at the same time as me.
It looks like they were A/B testing with fluvoxamine, with some "non active agent" as a placebo. Which, again, both of these drugs are useless as an antiviral unless they prove that these were taken within 4 days of infection.
From the paper:
Study staff verified eligibility criteria including ... SARS-CoV-2 infection within 10 days (positive polymerase chain reaction or antigen test result, including home-based tests)
Infection is when symptoms start, not the time of exposure.
Within 10 days of symptoms/infection is way too long of a window. If they are waiting on a PCR test result, I imagine that moves the fastest time to treat in the wrong direction.
In my opinion, if you get so much as a slight headache, start taking IVM right away, and take a test and add fluvoxamine and/or nitazoxanide (per FLCCC protocols) if the test comes back positive. Personally, I skip the tests because I only get headaches when sick and little else was floating around in 2020-2022. In 2023, I would still skip the test and assume covid if someone else tested positive that I might have been exposed to, or were exposed at the same time as me.
It looks like they were A/B testing with fluvoxamine, with some "non active agent" as a placebo. Which, again, is useless as an antiviral unless they prove that these were taken within 4 days of infection.